A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression

详细信息    查看全文

• 作者：Erica M. Richards ; Daniel C. Mathews ; David A. Luckenbaugh…
• 关键词：Anxiety ; Anxious depression ; Anxiolytic ; Major depressive disorder ; Opiate ; BDNF ; EEG ; Preclinical ; Biomarkers ; AZD2327
• 刊名：Psychopharmacology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：233
• 期：6
• 页码：1119-1130
• 全文大小：757 KB
• 参考文献：Alkermes PLC (2015) Alkermes announces positive results from study of ALKS 5461 for treatment of major depressive disorder
  Andreescu C, Lenze EJ, Dew MA, Begley AE, Mulsant BH, Dombrovski AY, Pollock BG, Stack J, Miller MD, Reynolds CF (2007) Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry 190:344–349CrossRef PubMed
  Baker AK, Hoffman VL, Meert TF (2002) Interactions of NMDA antagonists and an alpha 2 agonist with mu, delta and kappa opioids in an acute nociception assay. Acta Anaesthesiol Belg 53:203–212PubMed
  Blackburn TP, Cross AJ, Hille C, Slater P (1988) Autoradiographic localization of delta opiate receptors in rat and human brain. Neuroscience 27:497–506CrossRef PubMed
  Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A, Giovannini C, Rillosi L, Ventriglia M, Riva MA, Gennarelli M (2010) Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 11:763–773CrossRef PubMed
  Bosse KE, Jutkiewicz EM, Schultz-Kuszak KN, Mabrouk OS, Kennedy RT, Gnegy ME, Traynor JR (2014) Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism. Neuropharmacology 77:19–27PubMedCentral CrossRef PubMed
  Broom DC, Jutkiewicz EM, Folk JE, Traynor JR, Rice KC, Woods JH (2002) Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 26:744–755CrossRef PubMed
  Cahill CM, McClellan KA, Morinville A, Hoffert C, Hubatsch D, O’Donnell D, Beaudet A (2001) Immunohistochemical distribution of delta opioid receptors in the rat central nervous system: evidence for somatodendritic labeling and antigen-specific cellular compartmentalization. J Comp Neurol 440:65–84CrossRef PubMed
  Cai YC, Ma L, Fan GH, Zhao J, Jiang LZ, Pei G (1997) Activation of N-methyl-D-aspartate receptor attenuates acute responsiveness of delta-opioid receptors. Mol Pharmacol 51:583–587PubMed
  Clark-Raymond A, Halaris A (2013) VEGF and depression: a comprehensive assessment of clinical data. J Psychiatr Res 47:1080–1087CrossRef PubMed
  Cleary P, Guy W (1977) Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1:115–120
  Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, Zarate CAJ (2012) Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry 72:555–561PubMedCentral CrossRef PubMed
  de Gandarias JM, Echevarria E, Acebes I, Abecia LC, Casis O, Casis L (1999) Effects of fluoxetine administration on mu-opoid receptor immunostaining in the rat forebrain. Brain Res 817:236–240CrossRef PubMed
  Domschke K, Deckert J, Arolt V, Baune BT (2010) Anxious versus non-anxious depression: difference in treatment outcome. J Psychopharmacol 24:621–622CrossRef PubMed
  Duman RS (2004) Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromol Med 5:11–25CrossRef
  Elfving B, Buttenschon HN, Foldager L, Poulsen PH, Grynderup MB, Hansen AM, Kolstad HA, Kaerlev L, Mikkelsen S, Borglum AD, Wegener G, Mors O (2014) Depression and BMI influences the serum vascular endothelial growth factor level. Int J Neuropsychopharmacol 17:1409–1417CrossRef PubMed
  Escriba PV, Ozaita A, Garcia-Sevilla JA (2004) Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology 29:1512–1521CrossRef PubMed
  Farabaugh A, Alpert J, Wisniewski SR, Otto MW, Fava M, Baer L, Perlis R, Friedman E, Nyer M, Bitran S, Balasubramani GK, Inamori A, Trivedi M, Thase ME (2012) Cognitive therapy for anxious depression in STAR(*) D: what have we learned? J Affect Disord 142:213–218PubMedCentral CrossRef PubMed
  Fava M, Rankin MA, Wright EC, Alpert JE, Nierenberg AA, Pava J, Rosenbaum JF (2000) Anxiety disorders in major depression. Compr Psychiatry 41:97–102CrossRef PubMed
  Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, Warden D, Trivedi MH (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 165:342–351CrossRef PubMed
  Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL (2000) Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195–200CrossRef PubMed
  First MB, Spitzer RL, Gibbon M, Williams AR (2001) Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York State Psychiatric Institute, Biometrics Research, New York
  Fornaro M, Rocchi G, Escelsior A, Contini P, Ghio M, Colicchio S, De Berardis D, Amore M, Fornaro P, Martino M (2013) VEGF plasma level variations in duloxetine-treated patients with major depression. J Affect Disord 151:590–595CrossRef PubMed
  Fusa K, Takahashi I, Watanabe S, Aono Y, Ikeda H, Saigusa T, Nagase H, Suzuki T, Koshikawa N, Cools AR (2005) The non-peptidic delta opioid receptor agonist TAN-67 enhances dopamine efflux in the nucleus accumbens of freely moving rats via a mechanism that involves both glutamate and free radicals. Neuroscience 130:745–755CrossRef PubMed
  Goodman RR, Snyder SH, Kuhar MJ, Young WS 3rd (1980) Differentiation of delta and mu opiate receptor localizations by light microscopic autoradiography. Proc Natl Acad Sci U S A 77:6239–6243PubMedCentral CrossRef PubMed
  Greenlee A, Karp JF, Dew MA, Houck P, Andreescu C, Reynolds CF 3rd (2010) Anxiety impairs depression remission in partial responders during extended treatment in late-life. Depress Anxiety 27:451–456PubMedCentral CrossRef PubMed
  Gross-Isseroff R, Dillon KA, Israeli M, Biegon A (1990) Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Res 530:312–316CrossRef PubMed
  Herrmann CS, Demiralp T (2005) Human EEG gamma oscillations in neuropsychiatric disorders. Clin Neurophysiol 116:2719–2733CrossRef PubMed
  Hudzik TJ, Maciag C, Smith MA, Caccese R, Pietras MR, Bui KH, Coupal M, Adam L, Payza K, Griffin A, Smagin G, Song D, Swedberg MD, Brown W (2011) Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther 338:195–204CrossRef PubMed
  Hudzik TJ, Pietras MR, Caccese R, Bui KH, Yocca F, Paronis CA, Swedberg MD (2014) Effects of the delta opioid agonist AZD2327 upon operant behaviors and assessment of its potential for abuse. Pharmacol Biochem Behav 124:48–57CrossRef PubMed
  Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S, Nakataki M, Song H, Hokoishi K, Tanabe H, Sano A, Ohmori T (2007) Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31:658–663CrossRef PubMed
  Ionescu DF, Niciu MJ, Henter ID, Zarate CA (2013) Defining anxious depression: a review of the literature. CNS Spectr 1–9
  Ionescu DF, Niciu MJ, Richards EM, Zarate CA, Jr. (2014) Pharmacologic treatment of dimensional anxious depression: a review. Prim Care Companion CNS Disord 16
  Jutkiewicz EM (2006) The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv 6:162–169CrossRef PubMed
  Kahl KG, Bens S, Ziegler K, Rudolf S, Kordon A, Dibbelt L, Schweiger U (2009) Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 34:353–357CrossRef PubMed
  Kennedy SE, Koeppe RA, Young EA, Zubieta JK (2006) Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 63:1199–1208CrossRef PubMed
  Knoll AT, Muschamp JW, Sillivan SE, Ferguson D, Dietz DM, Meloni EG, Carroll FI, Nestler EJ, Konradi C, Carlezon WA Jr (2011) Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry 70:425–433PubMedCentral CrossRef PubMed
  Lee BH, Kim YK (2012) Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders. J Affect Disord 136:181–184CrossRef PubMed
  Lin JH, Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403–449PubMed
  Lutz PE, Kieffer BL (2013) Opioid receptors: distinct roles in mood disorders. Trends Neurosci 36:195–206PubMedCentral CrossRef PubMed
  Mansour A, Thompson RC, Akil H, Watson SJ (1993) Delta opioid receptor mRNA distribution in the brain: comparison to delta receptor binding and proenkephalin mRNA. J Chem Neuroanat 6:351–362CrossRef PubMed
  Naidu PS, Lichtman AH, Archer CC, May EL, Harris LS, Aceto MD (2007) NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action. Eur J Pharmacol 566:132–136PubMedCentral CrossRef PubMed
  National Institute for Clinical Excellence (NICE) (2004) Depression: management of depression in primary and secondary care. Clinical Guideline 23. NICE, London
  Ortega-Alvaro A, Acebes A, Saracibar G, Echevarria E, Casis L, Mico JA (2004) Effect of the antidepressant nefazodone on the density of cells expressing mu-opioid receptors in discrete brain areas processing sensory and affective dimensions of pain. Psychopharmacology Berl 176:305–311CrossRef PubMed
  Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF (1984) Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 230:341–348PubMed
  Quirion R, Zajac JM, Morgat JL, Roques BP (1983) Autoradiographic distribution of mu and delta opiate receptors in rat brain using highly selective ligands. Life Sci 33(Suppl 1):227–230CrossRef PubMed
  Reindl JD, Rowan K, Carey AN, Peng X, Neumeyer JL, McLaughlin JP (2008) Antidepressant-like effects of the novel kappa opioid antagonist MCL-144B in the forced-swim test. Pharmacology 81:229–235CrossRef PubMed
  Rush AJ, Wisniewski SR, Zisook S, Fava M, Sung SC, Haley CL, Chan HN, Gilmer WS, Warden D, Nierenberg AA, Balasubramani GK, Gaynes BN, Trivedi MH, Hollon SD (2012) Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. Psychol Med 42:1131–1149CrossRef PubMed
  Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J (2004) Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 95:374–380CrossRef PubMed
  Sanderson WC, Beck AT, Beck J (1990) Syndrome comorbidity in patients with major depression or dysthymia: prevalence and temporal relationships. Am J Psychiatry 147:1025–1028CrossRef PubMed
  Smagin GN, Song D, Medd A, Cross AJ, Hudzik T, Mrzljak L (2008) Neurochemical validation of centrally active delta-opioid receptor agonists as novel treatment of anxiety disorders. Eur Neuropsychopharmacol 18:S496CrossRef
  Taylor S, Abramowitz JS, McKay D (2012) Non-adherence and non-response in the treatment of anxiety disorders. J Anxiety Disord 26:583–589CrossRef PubMed
  Tejedor-Real P, Mico JA, Smadja C, Maldonado R, Roques BP, Gilbert-Rahola J (1998) Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model. Eur J Pharmacol 354:1–7CrossRef PubMed
  Torregrossa MM, Isgor C, Folk JE, Rice KC, Watson SJ, Woods JH (2004) The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology 29:649–659CrossRef PubMed
  Torregrossa MM, Folk JE, Rice KC, Watson SJ, Woods JH (2005) Chronic administration of the delta opioid receptor agonist (+)BW373U86 and antidepressants on behavior in the forced swim test and BDNF mRNA expression in rats. Psychopharmacology Berl 183:31–40PubMedCentral CrossRef PubMed
  Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH (2006) Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. Brain Res 1069:172–181PubMedCentral CrossRef PubMed
  Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243–1252CrossRef PubMed
  Ventriglia M, Zanardini R, Pedrini L, Placentino A, Nielsen MG, Gennarelli M, Bocchio-Chiavetto L (2009) VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry 33:146–149CrossRef PubMed
  
• 作者单位：Erica M. Richards (1)
  Daniel C. Mathews (1) (3)
  David A. Luckenbaugh (1)
  Dawn F. Ionescu (1) (4)
  Rodrigo Machado-Vieira (1)
  Mark J. Niciu (1)
  Wallace C. Duncan (1)
  Neal M. Nolan (1)
  Jose A. Franco-Chaves (1) (5)
  Thomas Hudzik (2) (6)
  Carla Maciag (2) (7)
  Shuang Li (2)
  Alan Cross (2)
  Mark A. Smith (2)
  Carlos A. Zarate Jr. (1)
  
  1. Experimental Therapeutics and Pathophysiology Branch, Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, 10 Center Drive CRC, Room 7-5545, Bethesda, MD, 20892, USA
  3. Lundbeck LLC, Chicago, IL, USA
  4. Massachusetts General Hospital, Boston, MA, USA
  5. Veteran Affairs Caribbean Healthcare System, San Juan, Puerto Rico
  2. AstraZeneca Neuroscience Innovative Medicines, Cambridge, MA, USA
  6. AbbVie, Chicago, IL, USA
  7. Sage Therapeutics, Cambridge, MA, USA
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Pharmacology and Toxicology
  Psychiatry
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-2072

文摘

Rationale Patients with anxious major depressive disorder (AMDD) have more severe symptoms and poorer treatment response than patients with non-AMDD. Increasing evidence implicates the endogenous opioid system in the pathophysiology of depression. AZD2327 is a selective delta opioid receptor (DOR) agonist with anxiolytic and antidepressant activity in animal models.